Method for detecting a progressive, chronic dementia disease, and corresponding peptides and detection agents

US7202044B2 · kind B2 · utility

Assignee

• Biovision, AG · DE

Inventors

• Norbert Lamping · Hannover, DE
• Hans-Dieter Zucht · Hannover, DE
• Harmut Selle · Hannover, DE
• Michael Jürgens · Schwetzingen, DE
• Gabriele Heine · Hannover, DE
• Rudiger Hess · Hannover, DE

Key dates

• Filing date: May 8, 2002
• Grant date: Apr 10, 2007
• Expiry date: Jan 7, 2023

Classification

• Technology area (CPC G): Physics
• CPC primary: G01N2800/2814
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The invention relates to defined peptides and the quantitative determination thereof in body fluids of patients suffering from progredient chronic dementia, in relation to the concentration of said peptides in a control group. The inventive peptides come from a protein precursor having the corresponding gene, are processed in a specific manner, and are optionally post-translationally modified, especially phosphorylized. An increase in the concentrations of these peptides or the corresponding non-processed protein indicates progredient chronic dementia. Progredient chronic dementia is detected by identifying the peptides and/or the protein individually or in combinations. The invention also relates to the use of said peptides for controlling the course of progredient chronic dementia and for the prognosis of progredient chronic dementia, especially for complementing or replacing mini-mental scores, and for developing therapeutic agents to combat progredient chronic dementia such as Alzheimer's disease.